El Bairi Khalid, Haynes Harry R, Blackley Elizabeth, Fineberg Susan, Shear Jeffrey, Turner Sophia, de Freitas Juliana Ribeiro, Sur Daniel, Amendola Luis Claudio, Gharib Masoumeh, Kallala Amine, Arun Indu, Azmoudeh-Ardalan Farid, Fujimoto Luciana, Sua Luz F, Liu Shi-Wei, Lien Huang-Chun, Kirtani Pawan, Balancin Marcelo, El Attar Hicham, Guleria Prerna, Yang Wenxian, Shash Emad, Chen I-Chun, Bautista Veronica, Do Prado Moura Jose Fernando, Rapoport Bernardo L, Castaneda Carlos, Spengler Eunice, Acosta-Haab Gabriela, Frahm Isabel, Sanchez Joselyn, Castillo Miluska, Bouchmaa Najat, Md Zin Reena R, Shui Ruohong, Onyuma Timothy, Yang Wentao, Husain Zaheed, Willard-Gallo Karen, Coosemans An, Perez Edith A, Provenzano Elena, Ericsson Paula Gonzalez, Richardet Eduardo, Mehrotra Ravi, Sarancone Sandra, Ehinger Anna, Rimm David L, Bartlett John M S, Viale Giuseppe, Denkert Carsten, Hida Akira I, Sotiriou Christos, Loibl Sibylle, Hewitt Stephen M, Badve Sunil, Symmans William Fraser, Kim Rim S, Pruneri Giancarlo, Goel Shom, Francis Prudence A, Inurrigarro Gloria, Yamaguchi Rin, Garcia-Rivello Hernan, Horlings Hugo, Afqir Said, Salgado Roberto, Adams Sylvia, Kok Marleen, Dieci Maria Vittoria, Michiels Stefan, Demaria Sandra, Loi Sherene
Department of Medical Oncology, Mohammed VI University Hospital, Faculty of Medicine and Pharmacy, Mohammed Ist University, Oujda, Morocco.
Department of Cellular Pathology, Great Western Hospital, Swindon, UK.
NPJ Breast Cancer. 2021 Dec 1;7(1):150. doi: 10.1038/s41523-021-00346-1.
The advent of immune-checkpoint inhibitors (ICI) in modern oncology has significantly improved survival in several cancer settings. A subgroup of women with breast cancer (BC) has immunogenic infiltration of lymphocytes with expression of programmed death-ligand 1 (PD-L1). These patients may potentially benefit from ICI targeting the programmed death 1 (PD-1)/PD-L1 signaling axis. The use of tumor-infiltrating lymphocytes (TILs) as predictive and prognostic biomarkers has been under intense examination. Emerging data suggest that TILs are associated with response to both cytotoxic treatments and immunotherapy, particularly for patients with triple-negative BC. In this review from The International Immuno-Oncology Biomarker Working Group, we discuss (a) the biological understanding of TILs, (b) their analytical and clinical validity and efforts toward the clinical utility in BC, and (c) the current status of PD-L1 and TIL testing across different continents, including experiences from low-to-middle-income countries, incorporating also the view of a patient advocate. This information will help set the stage for future approaches to optimize the understanding and clinical utilization of TIL analysis in patients with BC.
免疫检查点抑制剂（ICI）在现代肿瘤学中的出现显著提高了多种癌症患者的生存率。一部分乳腺癌（BC）女性患者存在淋巴细胞免疫原性浸润，并伴有程序性死亡配体1（PD-L1）表达。这些患者可能会从靶向程序性死亡1（PD-1）/PD-L1信号轴的ICI治疗中获益。肿瘤浸润淋巴细胞（TILs）作为预测和预后生物标志物的应用一直受到深入研究。新出现的数据表明，TILs与细胞毒性治疗和免疫治疗的反应均相关，尤其是对于三阴性乳腺癌患者。在国际免疫肿瘤生物标志物工作组的这篇综述中，我们讨论了：（a）对TILs的生物学理解；（b）它们的分析和临床有效性以及在BC中实现临床应用的努力；（c）不同大洲PD-L1和TIL检测的现状，包括来自低收入和中等收入国家的经验，其中还纳入了患者倡导者的观点。这些信息将有助于为未来优化对BC患者TIL分析的理解和临床应用的方法奠定基础。
NPJ Breast Cancer. 2021-12-1
Cancer Treat Res. 2025
NPJ Breast Cancer. 2025-7-24
Lancet Oncol. 2020-11
NPJ Breast Cancer. 2020-5-12
Zotero 插件